Using AChR antibody titres to predict treatment responses in myasthenia gravis

2021 ◽  
pp. jnnp-2021-326480
Author(s):  
Angela Vincent
Keyword(s):  
Myasthenia Gravis ◽  
Achr Antibody ◽  
Antibody Titres ◽  
Treatment Responses

scholarly journals Effective Early Treatment of AChR Antibody-Positive Myasthenia Gravis with Rituximab; the Experience from a Neuroimmunology Clinic in a Developing Country

2021 ◽  
Vol 13 ◽  
pp. 117957352110160
Author(s):  
Thomas Mathew ◽  
Kurian Thomas ◽  
Saji K John ◽  
Shruthi Venkatesh ◽  
Raghunandan Nadig ◽  
...  
Keyword(s):  
Observational Study ◽  
Myasthenia Gravis ◽  
Treatment Option ◽  
Early Treatment ◽  
Early Stage ◽  
Tertiary Care ◽  
Response To Treatment ◽  
Myasthenic Crisis ◽  
Achr Antibody ◽  
Significant Difference

Background: Rituximab is reserved for treating refractory myasthenia gravis (MG) patients. Here we report our experience with rituximab in AChR antibody positive generalized MG (gMG) and impending myasthenic crisis (IMC). Methods: This retrospective, observational study, conducted at a tertiary care, neuroimmunology clinic, analyzed the data of patients with AChR antibody positive gMG, treated with rituximab between 1st January 2016 and 30th October 2018. Results: Eleven patients with AChR antibody positive gMG received rituximab. Mean age of the cohort was 50.54 ± 18.71 years with 9 males. Seven out of 11 patients received rituximab in the early stage (<2 years from onset) and had good response to treatment. Four of the 5 patients with IMC improved with rituximab alone. In the 10 patients who regularly followed up, there was a significant difference between the QMG scores at baseline and at 1, 2, 6, 12, and 18 months ( P < .0001). Conclusion: Rituximab appears to be a potentially effective early treatment option for AChR antibody positive generalized MG and impending myasthenic crisis.

scholarly journals Myasthenia gravis: acetylcholine-receptor antibody titres after thymectomy.

BMJ ◽  
1977 ◽  
Vol 1 (6075) ◽  
pp. 1512-1512 ◽  
Author(s):  
G K Scadding ◽  
H C Thomas ◽  
C W Havard
Keyword(s):  
Myasthenia Gravis ◽  
Acetylcholine Receptor ◽  
Receptor Antibody ◽  
Acetylcholine Receptor Antibody ◽  
Antibody Titres

scholarly journals The Effect of Plasmapheresis on Post-Thymectomy Ocular Dysfunction

1981 ◽  
Vol 8 (2) ◽  
pp. 169-172 ◽  
Author(s):  
C.W. Olanow ◽  
A.D. Roses ◽  
J.W. Fay
Keyword(s):  
Myasthenia Gravis ◽  
Clinical Improvement ◽  
Antibody Titer ◽  
Clinical State ◽  
Achr Antibody ◽  
The Individual ◽  
Thymic Factor ◽  
Ocular Signs

SUMMARY:Five myasthenia gravis patients with post-thymectomy residual ocular signs were treated with plasmapheresis. Despite a significant reduction in AChR antibody titer, there was no clinical improvement. Subsequently, there was a dramatic response to prednisone. The AChR antibody titer did not correlate with the clinical state of the individual patient. It is suggested that plasmapheresis may operate by removing a thymic factor and that prednisone acts by a different mechanism.

Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: Outcomes in 102 patients

2010 ◽  
Vol 41 (5) ◽  
pp. 593-598 ◽  
Author(s):  
Michael K. Hehir ◽  
Ted M. Burns ◽  
Joshua Alpers ◽  
Mark R. Conaway ◽  
Michael Sawa ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Myasthenia Gravis ◽  
Achr Antibody

Anti AChR antibody: Relevance to diagnosis and clinical aspects of myasthenia gravis

1988 ◽  
Vol 9 (2) ◽  
pp. 141-145 ◽  
Author(s):  
R. Mantegazza ◽  
D. Pareyson ◽  
F. Baggi ◽  
P. Romagnoli ◽  
D. Peluchetti ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Clinical Aspects ◽  
Achr Antibody

scholarly journals Electrophysiological investigation for autonomic dysfunction in patients with myasthenia gravis : A prospective study

2021 ◽  
Vol 74 (1-2) ◽  
pp. 33-40
Author(s):  
Mecbure Nalbantoglu ◽  
Mehmet Ali Akalin ◽  
Aysegul Gunduz ◽  
Meral Kiziltan
Keyword(s):  
Myasthenia Gravis ◽  
Autonomic Dysfunction ◽  
Acetylcholinesterase Inhibitors ◽  
Sympathetic Skin Response ◽  
Autoimmune Disorder ◽  
Control Group ◽  
Negative Group ◽  
Achr Antibody ◽  
Skin Response ◽  
A Prospective Study

Myasthenia gravis (MG) is an autoimmune disorder of neuromuscular transmission. Autonomic dysfunction is not a commonly known association with MG. We conducted this study to evaluate autonomic functions in MG & subgroups and to investigate the effects of acetylcholinesterase inhibitors. This study comprised 30 autoimmune MG patients and 30 healthy volunteers. Autonomic tests including sympathetic skin response (SSR) and R-R interval variation analysis (RRIV) was carried out. The tests were performed two times for patients who were under acetylcholinesterase inhibitors during the current assessment. The RRIV rise during hyperventilation was better (p=0.006) and Valsalva ratio (p=0.039) was lower in control group. The SSR amplitudes were lower thereafter drug intake (p=0.030). As much as time went by after drug administration prolonged SSR latencies were obtained (p=0.043).Valsalva ratio was lower in the AchR antibody negative group (p=0.033). The findings showed that both ocular/generalized MG patients have a subclinical parasympathetic abnormality prominent in the AchR antibody negative group and pyridostigmine has a peripheral sympathetic cholinergic noncumulative effect.

Sign in / Sign up

Export Citation Format

Share Document